Fully Human Antibody Library
Preclinical (PCC) and Clinical Assets
Antibody Asset Licensing & Co-Development
Biocytogen’s fully human antibody library comprises 1M+ antibody sequences against 1000+ antigens, applicable across multiple therapeutic areas. These antibodies are generated using proprietary RenMice® strains, each engineered to lack a specific target gene. This fully human, hyperimmune, target-specific (HiTS) platform increases the likelihood of generating antibodies with favorable developability characteristics, including:
- Lower risk of immunogenicity
- Cross-species recognition to facilitate preclinical efficacy and safety evaluation
- High specificity, affinity, and diversity, owing to comprehensive coverage of immunoglobulin variable region genes in RenMice models
- Amenable to assembly into multiple modalities, including bispecific antibodies (bsAbs)/engagers, bispecific ADCs (bsADCs), Hu-VHH platform, and TCR-mimic (TCRm) antibodies for novel therapeutic applications
- Facilitates discovery against a broad range of challenging and high-interest drug targets, including membrane, extracellular, and intracellular proteins
